Della Porta et al. reported similar findings where mutations in TP53 as well as ASXL1 and RUNX1 were independent risk factors for poor OS in patients with MDS or secondary AML (N = 401) who received allo-HCT [63]. Here, TP53 is linked to myelodysplastic syndrome.